Pablo Tebas, MD
Associate Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA

Research Topics

• Antiretroviral therapy
• Treatment of virologic failure
• Metabolic complications of antiretroviral therapy
  
  
  

Lecture and Writing Topics

• Antiretroviral therapy (initiation, sequencing, modeling)
• Metabolic complications of antiretroviral therapy
  
  
  

Current Professional Summary

Dr Tebas is an Associate Professor of Medicine at the University of Pennsylvania School of Medicine and Principal Investigator in the AIDS Clinical Trial Unit at the University of Pennsylvania.


Committees and Organizations

• Complications of HIV Disease RAC Viral Diseases Pathogen Study Group, National Institute of Allergy and Infectious Diseases, AIDS Clinical Trial Group (1997–)
• Complications of HIV Disease RAC Metabolic Study Group, National Institute of Allergy and Infectious Diseases, AIDS Clinical Trial Group (1998–)
  
  
  

Honors and Awards

• Premio Extraordinario Fin la carrera (Summa Cum Laude), Universidad Autónoma de Madrid (1986)
• SmithKline Beecham Junior Faculty Award (2000)
  
  
  

Education

• Universidad Autónoma de Madrid, Graduate of the School of Medicine and Surgery (1985)
• Universidad Autónoma de Madrid, Clínica Puerta de Hierro, Residency in Internal Medicine, (1987–1992)
• Universidad Autonoma de Madrid, MD (1991)
• Washington University, Fellowship in Infectious Diseases (1992–1996)
  
  
  

Selected Publications

1. Tebas P, Niece R, Storch G. Decision analysis about the use of CSF PCR in the diagnosis of herpes simplex encephalitis. Am J Med. 1998;105:287-295.
2. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JPA, Holohan MK, Leavitt R, Boone G, Richman DD. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med. 1998;339:1261-1268.
3. Yarasheski KE, Teas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr. 1999;21:209-216.
4. Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis. 1999;28:1152-1154.
5. Powderly WG, Tebas P. Nelfinavir, a new protease inhibitor: early clinical results. AIDS. 1999;13:S41-S48.
6. Havlir D, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi J-P, Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283:229-234.
7. Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combinaton with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS. 2000;14:1591-1600.
8. Ioannidis JPA, Havlir DV, Tebas P, Hirsch MS, Collier AC, Richman DD. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. AIDS. 2000;14:1481-1488.
9. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23-F28.
10. Tebas P, Powderly WG. Claxton S. Marin D. Tantisiriwat W. Teitelbaum SL. Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.